#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary adrenal insufficiency Leukocyte adhesion deficiency type I Burkitt's lymphoma refractory Pneumonia Granulomatosis with polyangiitis Frontotemporal dementia Pouchitis Brain stem glioma Hyperphagia B-cell small lymphocytic lymphoma recurrent Hodgkin's disease refractory Ovarian cancer Immune-mediated myasthenia gravis Diffuse large B-cell lymphoma Fragile X syndrome More trials…

    Learn about Rare Diseases

    Congenital hypotransferrinaemia – Trials in Disease Medulloblastoma recurrent – Diagnostics Biotinidase deficiency – Treatment Richter’s syndrome – Treatment Nephroblastoma – Trials in Disease Nodal marginal zone B-cell lymphoma – Diagnostics Indolent systemic mastocytosis – Treatment Glomerulonephritis rapidly progressive – Basic Information Haemophilia A without inhibitors Osteosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ferric Derisomaltose Ketamine Retinol Palmitate Viltolarsen Alirocumab Antithymocyte Immunoglobulin Palbociclib Cytisine Mk-1084 Fenebrutinib Flecainide Abc-35B-116 Sodium Phosphate Dodecahydrate Obinutuzumab HYDROGEN Alectinib Ondansetron Hydrochloride Sepiapterin CICLOPIROX Dl-Alpha Tocopherol Acetate More therapies…

    Learn about Your Condition

    Metabolic surgery Solitary fibrous tumour Facial paresis Malignant melanoma Peripheral ischaemia Atrial septal defect Colon cancer stage II Amnestic disorder Athetosis Portal hypertension Leukaemia Nervous system disorder Adenovirus infection Yellow fever Dizziness More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Biliary cancer metastatic
    • Biliary neoplasm
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Gemcitabine
    Belgium Denmark France Germany Italy Norway +2

  • Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Nivolumab
    France Italy

  • Study of ONCOFID-P-B for Patients with Bladder Carcinoma in Situ Unresponsive to BCG Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Paclitaxel Obaluronate
    France Italy Poland Spain

  • Study of Retifanlimab, Carboplatin, and Paclitaxel for Patients with Inoperable or Metastatic Anal Canal Squamous Cell Carcinoma Not Treated with Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Retifanlimab
    Belgium Denmark France Germany Italy Norway +2

  • Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Docetaxel
    • Paclitaxel
    • Pertuzumab
    Belgium Denmark France Germany Hungary Italy +3

  • Study of Fulvestrant and Abemaciclib for Women with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Fulvestrant
    Belgium Greece Italy Poland Spain

  • Study of AZD5305 Alone and with Other Cancer Drugs for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    • Neoplasm malignant
    Investigated Drugs:
    • Camizestrant
    • Datopotamab Deruxtecan
    • Paclitaxel
    Czechia Hungary Italy Poland Spain

  • A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Gen1047
    Belgium Denmark France Italy The Netherlands Poland +1

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
    Belgium Bulgaria Czechia Finland Germany Greece +5

  • Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Ro7247669
    • Tiragolumab
    Denmark France Germany Greece Italy Poland +1
Previous Page
1 … 32 33 34 35 36 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!